刘严慈,彭红玉,柳景华,李文铮,吴铮,赵东晖,程子超

• 1:首都医科大学附属北京安贞医院冠心病中心

摘要(Abstract)：

目的 采用慢性完全闭塞病变学术联盟（CTO-ARC）专家共识定义，按照CTOARC围术期心肌梗死（PMI）标准，评价慢性完全闭塞（CTO）病变行经皮冠状动脉介入治疗（PCI）PMI的发生率，并对相关危险因素进行分析。方法 根据CTO-ARC标准，回顾性分析首都医科大学附属北京安贞医院冠心病中心自2019年1—6月所有通过PCI成功完成血运重建的CTO病变患者的临床基线特征、造影结果以及手术操作特点，应用多因素Logistic回归分析识别PMI的独立危险因素。结果 纳入通过PCI成功完成血运重建的CTO病变415例，PMI发生率4.8%。经多因素Logistic回归分析，供血血管闭塞（OR 48.818,95%CI 2.365～1 007.888,P=0.012）、边支血管损伤（OR 20.332,95%CI 4.439～93.132,P<0.01）、术后心肌梗死溶栓治疗试验（TIMI）血流分级<Ⅲ级（OR 33.310,95%CI6.209～178.689,P<0.01）及支架长度（OR 1.020,95%CI1.005～1.035,P=0.011）与CTO病变血运重建后PMI密切相关。结论 供血血管闭塞、边支血管损伤、术后TIMI血流分级<Ⅲ级及支架长度与CTO病变血运重建后PMI密切相关。

关键词(KeyWords)： 慢性完全闭塞病变;经皮冠状动脉介入治疗;围术期心肌梗死

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘严慈,彭红玉,柳景华,李文铮,吴铮,赵东晖,程子超

参考文献(References)：

• [1] Patel VG, Brayton KM, Tamayo A, et al. Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions:a weighted meta-analysis of 18,061 patients from 65 studies[J].JACC Cardiovasc Interv, 2013, 6(2):128-136.
• [2] Lee DW, Cavender MA. Periprocedural myocardial infarction in contemporary practice[J]. Interv Cardiol Clin, 2019, 8(2):209-223.
• [3] Babu GG, Walker JM, Yellon DM, et al. Peri-procedural myocardial injury during percutaneous coronary intervention:an important target for cardioprotection[J]. Eur Heart J, 2011,32(1):23-31.
• [4] Hara H, Serruys PW, Takahashi K, et al. Impact o f peri-procedural myocardial infarction on outcomes after revascularization[J]. J Am Coll Cardiol, 2020, 76(14):1622-1639.
• [5] Ybarra LF, Rinfret S, Brilakis ES, et al. Defi nitions and clinical trial design principles for coronary artery chronic total occlusion therapies:CTO-ARC Consensus Recommendations[J].Circulation, 2021, 143(5):479-500.
• [6] Wu EB, Brilakis ES, Mashayekhi K,et al. Global chronic total occlusion crossing algorithm:JACC state-of-the-art review[J].J Am Coll Cardiol, 2021, 78(8):840-853.
• [7] Song L, Wang Y, Guan C, et al. Impact of periprocedural myocardial injury and infarction defi nitions on long-term mortality after chronic total occlusion percutaneous coronary intervention[J].Circ Cardiovasc Interv, 2021, 14(11):e010923.
• [8] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2018, 76(12):1585-1664.
• [9] Lee SW, Lee PH, Kang SH, et al. Determinants and prognostic significance of periprocedural myocardial injury in patients with successful percutaneous chronic total occlusion interventions[J]. JACC Cardiovasc Interv, 2016, 9(21):2220-2228.
• [10]陈孟莹，臧雁翔，李为民.解读《2021年欧洲心脏病学会心脏细胞学工作组联合欧洲经皮心血管介入学会共识文件：经皮冠状动脉介入治疗与预后相关的围术期心肌损伤和梗死》[J].中国介入心脏病学杂志，2022,30(3):219-222.
• [11] Thygesen K, Alpert JS, Jaffe AS,et al. Fourth Universal Defi nition of Myocardial Infarction(2018)[J]. Circulation,2018, 138(20):e618-e651.
• [12] Moussa ID, Klein LW, Shah B,et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization:an expert consensus document from the Society for Cardiovascular Angiography and Interventions(SCAI)[J]. J Am Coll Cardiol, 2013, 62(17):1563-1570.
• [13] Garcia-Garcia HM, McFadden EP, von Birgelen C,et al. Impact of periprocedural myocardial biomarker elevation on mortality following elective percutaneous coronary intervention[J].JACC Cardiovasc Interv, 2019, 12(19):1954-1962.
• [14] Koskinas KC, Ndrepepa G, R?ber L, et al. Prognostic impact of periprocedural myocardial infarction in patients undergoing elective percutaneous coronary interventions[J]. Circ Cardiovasc Interv, 2018, 11(12):e006752.
• [15] Wang HY, Xu B, Dou K, et al. Implications of periprocedural myocardial biomarker elevations and commonly used mi defi nitions after left main PCI[J]. JACC Cardiovasc Interv,2021, 14(15):1623-1634.
• [16] Soud M, Ho G, Hideo-Kajita A, et al. Periprocedural myocardial injury:pathophysiology, prognosis, and prevention[J]. Cardiovasc Revasc Med, 2020, 21(8):1041-1052.
• [17] Karacsonyi J, Vemmou E, Nikolakopoulos I, et al. Current challenges and prevention strategies for chronic total occlusion(CTO)complications[J]. Expert Rev Cardiovasc Ther,2021, 19(4):3373-3347.
• [18]郭云飞，彭红玉，赵烨婧，等.冠状动脉慢性完全闭塞合并分叉病变介入干预策略及围术期并发症分析[J].中国介入心脏病学杂志，2021, 29(11):617-623.
• [19] Lee PH, Lee SW, Yun SC,et al. Full metal jacket with drugeluting stents for coronary chronic total occlusion[J]. JACC Cardiovasc Interv, 2017, 10(14):1405-1412.
• [20] Barbato E, Mehilli J, Sibbing D, et al. Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome(NSTE-ACS):a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021, 42(14):1368-1378.